BSPM [Biostar Pharmaceuticals] 10-K: FORM 10-K (Mark One) x December 31, 2013

[FORM 10-K (Mark One) x December 31, 2013 For the fiscal year ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 86-29-33686638 (Former name, former] [CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-192963) of Biostar Pharmaceuticals, Inc. of our report dated March 31, 2014 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K of Biostar] [CERTIFICATION I, Ronghua Wang, certify that: 1. R e I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to] [CERTIFICATION I, Qinghua Liu, certify that: 1. R I have reviewed this Annual 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: March 31, 2014 Ronghua Wang Chief Executive Officer EX-32.1 5 ex32-1.htm EX-32.1] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Dated: March 31, 2014 Qinghua Liu Interim Chief Financial Officer (principal financial officer) EX-32.2 6 ex32-2.htm EX-32.2]

By | 2016-03-28T18:35:49+00:00 March 31st, 2014|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)

[CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC. 208 Summitrail Lane Dawsonville, GA 30524 Phone (770) 815-0885 Mr. Ronghua Wang Chairman and CEO Biostar Pharmaceuticals, Inc No. 588 Shiji Xi Avenue Xianyang, 712046 Phone: 86 29 3368 6638 Dear Mr. Wang: “ Moody Capital Solutions, Inc. Axiom Capital Management, Inc Biostar Pharmaceuticals, Inc. This letter (the The terms of such] [BIOSTAR PHARMACEUTICALS, INC. Issuance Date Date of Issuance: March [___], 2014 (“ Company Holder 1 16 Securities Purchase Agreement Biostar Pharmaceuticals, Inc., a Maryland corporation (the “ 1. (a) Mechanics of Exercise 1 (f) Exercise Notice Aggregate Exercise Price 1 (d) st . Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1] [March 10, 2014 Board of Directors Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People’s Republic of China 712046 Company Shares Shares Shares Securities Purchase Agreement Registration Statement Commission Act Base Prospectus Prospectus Supplement Prospectus Schiff Hardin LLP EX-5.1 4 ex5-1.htm EX-5.1] [SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT Agreement Company Buyer Buyers This RECITALS Registration Statement 1933 Act SEC Common Shares Common Stock B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms stated in this Agreement, (i) the aggregate number of shares of Common Stock (as defined below) set forth opposite such Buyer’s name in column] [Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1 million. The net proceeds from this offering will be used for working capital and other general corporate purposes. The completion of the offering will occur on or before March 13, 2014. Moody Capital Solutions, Inc.] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): March 10, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T18:40:05+00:00 March 10th, 2014|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] 8-K: CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC.

[CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC. 208 Summitrail Lane Dawsonville, GA 30524 Phone (770) 815-0885 Mr. Ronghua Wang Chairman and CEO Biostar Pharmaceuticals, Inc No. 588 Shiji Xi Avenue Xianyang, 712046 Phone: 86 29 3368 6638 Dear Mr. Wang: “ Moody Capital Solutions, Inc. Axiom Capital Management, Inc Biostar Pharmaceuticals, Inc. This letter (the The terms of such] [BIOSTAR PHARMACEUTICALS, INC. Issuance Date Date of Issuance: March [___], 2014 (“ Company Holder 1 16 Securities Purchase Agreement Biostar Pharmaceuticals, Inc., a Maryland corporation (the “ 1. (a) Mechanics of Exercise 1 (f) Exercise Notice Aggregate Exercise Price 1 (d) st . Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1] [March 10, 2014 Board of Directors Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People’s Republic of China 712046 Company Shares Shares Shares Securities Purchase Agreement Registration Statement Commission Act Base Prospectus Prospectus Supplement Prospectus Schiff Hardin LLP EX-5.1 4 ex5-1.htm EX-5.1] [SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT Agreement Company Buyer Buyers This RECITALS Registration Statement 1933 Act SEC Common Shares Common Stock B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms stated in this Agreement, (i) the aggregate number of shares of Common Stock (as defined below) set forth opposite such Buyer’s name in column] [Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1 million. The net proceeds from this offering will be used for working capital and other general corporate purposes. The completion of the offering will occur on or before March 13, 2014. Moody Capital Solutions, Inc.] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): March 10, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T18:41:02+00:00 March 10th, 2014|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] 424B5: (Original Filing)

[Prospectus Supplement To Prospectus Dated December 31, 2013 Registration No. 333-192963 Biostar Pharmaceuticals, Inc. 1,650,000 shares of common stock Our shares of common stock are currently traded on the Nasdaq Capital Market under the symbol “BSPM.” On March 7, 2014, the closing sale price of our shares of common stock was $2.97 per share. Risk Factors Investing in our securities]

By | 2016-03-28T18:37:11+00:00 March 10th, 2014|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] 424B5: Prospectus Supplement To Prospectus Dated December 31, 2013

[Prospectus Supplement To Prospectus Dated December 31, 2013 Registration No. 333-192963 Biostar Pharmaceuticals, Inc. 1,650,000 shares of common stock Our shares of common stock are currently traded on the Nasdaq Capital Market under the symbol “BSPM.” On March 7, 2014, the closing sale price of our shares of common stock was $2.97 per share. Risk Factors Investing in our securities]

By | 2016-03-28T18:38:43+00:00 March 10th, 2014|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)

[Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating Results as Compared With Last Year’s USD$21.8 million loss from operations XIANYANG, China, February 20, 2014 –Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 20, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T18:42:24+00:00 February 20th, 2014|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] 8-K: Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth

[Biostar Pharmaceuticals, Inc. Expects 2013 Yearly Revenue Growth above 20% with Break Even Operating Results as Compared With Last Year’s USD$21.8 million loss from operations XIANYANG, China, February 20, 2014 –Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) ("Biostar" or "the Company"), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 20, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T18:43:16+00:00 February 20th, 2014|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] EFFECT: (Original Filing)

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica, sans-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif} .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold} .FormName {font-size: large; font-family: arial, helvetica, sans-serif;]

By | 2016-03-28T18:44:26+00:00 January 3rd, 2014|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals] EFFECT: .FormData {color: blue; background-color: white; font-size: small; font-family:

[.FormData {color: blue; background-color: white; font-size: small; font-family: Times, serif} .SmallFormData {color: blue; background-color: white; font-size: x-small; font-family: Times, serif} .FootnoteData {color: green; background-color: white; font-size: x-small; font-family: Times, serif} .FormText {font-size: x-small; font-family: arial, helvetica, sans-serif} .SmallFormText {font-size: xx-small; font-family: arial, helvetica, sans-serif} .FormTitle {font-size: medium; font-family: arial, helvetica, sans-serif; font-weight: bold} .FormName {font-size: large; font-family: arial, helvetica, sans-serif;]

By | 2016-03-28T18:46:19+00:00 January 3rd, 2014|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] S-3/A: (Original Filing)

[Pre-effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Inc. Maryland (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Code Number) 20-8747899 (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province The People’s Republic of China, 712046 011-86-29-33686638 (Address, including zip code, and telephone number,] [[Schiff Hardin LLP Letterhead] December 31, 2013 Board of Directors Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province, P.R. of China, 712046 Re: Registration Statement on Form S-3 Ladies and Gentlemen: Based on the foregoing and subject to the qualifications set forth below, we are of the opinion that, when any applicable state securities or Blue Sky]

By | 2016-03-03T10:27:59+00:00 December 31st, 2013|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar